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Letter to the Editor
Table 1
Genotype and Allele Frequency Distribution of the Polymorphisms Analyzed across SEMA5A on Chromosome 5
dbSNP
ACCESSION
NUMBER POSITION
GENOTYPE FREQUENCY
MINOR-ALLELE
FREQUENCY
OR P (95% CI)aControl 11 Control 12 Case 11 Case 12 Control Case
Finnish series:
rs3798097 9595529 .49 .35 .51 .35 .34 .32 .910 .610 (.63–1.31)
rs368226 9470056 .90 .10 .91 .09 .05 .05 .921 .838 (.42–2.02)
rs7702187 9385281 .69 .29 .74 .22 .16 .15 .901 .657 (.57–1.43)
rs1806151 9207659 .25 .50 .27 .53 .50 .47 1.160 .424 (.81–1.67)
rs786843 9093141 .68 .29 .66 .31 .18 .18 1.055 .814 (.67–1.65)
Taiwanese series:
rs3798097 9595529 .81 .16 .88 .10 .11 .07 .586 .025 (.37–.94)
rs368226 9470056 .51 .37 .49 .42 .30 .30 .995 .976 (.74–1.33)
rs7702187 9385281 .61 .35 .49 .44 .22 .30 1.534 .007 (1.12–2.10)
rs1806151 9207659 .62 .34 .62 .35 .21 .22 .958 .805 (.68–1.35)
rs786843 9093141 .89 .10 .88 .12 .06 .06 1.057 .846 (.61–1.65)
a Values in bold denote statistical significance.
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Conflicting Results Regarding the Semaphorin Gene
(SEMA5A) and the Risk for Parkinson Disease
To the Editor:
The strongest variant (rs7702187) associated with Par-
kinson disease (PD [MIM 168600]) reported in the
whole-genome association study by Maraganore et al.1
was evaluated in two independent case-control series of
patients from Finland and Taiwan, as were four other
variants located within SEMA5A (MIM 609297). The
Finnish series comprised 146 patients with sporadic PD
(mean age 67.2 years, range 38–88 years; 41% women)
and 135 neurologically normal, healthy control subjects
(mean age 65.8 years, range 37–80 years; 64% women).
All individuals were recruited from the neurological out-
patient clinics of the Helsinki University Central Hos-
pital and Seina¨joki Central Hospital. The Taiwanese se-
ries consisted of 303 patients with sporadic PD (mean
age 61.9 years, range 24–91 years; 46.2% women) and
171 control individuals (mean age 60.1 years, range 31–
86 years; 43.9% women). Patients were selected from
the neurological clinic of Chang-Gung Memorial Hos-
pital. Individuals with evidence of secondary parkinson-
ism or with atypical features such as early dementia,
ophthalmoplegia, early autonomic failure, and pyram-
idal signs were not included in this study. All patients
included in the study fulfilled PD diagnosis criteria.2 All
participants signed an informed consent form.
Taqman Assays-by-Design SNP Genotyping Assays
(Applied Biosystems) were employed for allelic discrim-
ination of all SNPs. Differences in allele and genotype
distributions were analyzed using the x2 test, and two-
tailed P values are presented. Haplotype frequency com-
parisons between cases and controls were performed
with PHASE version 2.1 software.3 One thousand per-
mutations were performed for each comparison. The
COCAPHASE module of the UNPHASED statistical
package was used for linkage-disequilibrium (LD) anal-
yses.4 Power calculations were performed with PS ver-
sion 2.1.30.5
Allele and genotype frequency information for each
of the markers is shown in table 1. None of the markers
showed any significant association with disease in the
Finnish series. However, we were able to replicate the
reported association with marker rs7702187 in the Tai-
wanese cohort (odds ratio [OR]p 1.53, 95% CI 1.12–
2.10, ). Genotype analysis showed that indi-Pp .007
viduals homozygous for the A allele had a significantly
decreased risk of PD compared with those heterozygous
or homozygous for the T allele (OR p 0.60, 95% CI
0.41–0.88, ). A significant association was alsoPp .009
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Table 2
Haplotype Frequency Distribution in Finnish and
Taiwanese Series
HAPLOTYPE
FREQUENCY
Finnisha Taiwaneseb
Control Cases Control Cases
CCACC .252 .267 .391 .339
CCAGC .212 .203 .069 .081
TCAGC .104 .096 .010 .005
TCACC .103 .109 .049 .024
CGACG .010 .013 .164 .163
CCTCC .038 .046 .105 .162
Otherc .281 .267 .097 .227
NOTE.—The order of SNPs is rs3798097,
rs368226, rs7702187, rs1806151, and rs786843.
a Global significance for haplotype frequency dif-
ferences: Pp .9
b Global significance for haplotype frequency dif-
ferences: Pp .091
c Other haplotypes with frequencies !5%.
found for the rs3798097 marker, which is located in the
5′ UTR region of SEMA5A (OR for the C allele was
1.71, 95% CI 1.06–2.73, ).Pp .025
Both populations showed a complete lack of LD for
any pairs of neighboring polymorphisms (all D′ values
were !0.5, independently of diagnostic group). Haplo-
type frequency comparisons did not reveal any signifi-
cant differences between patients and controls in the
Finnish series ( ) or between patients and con-Pp .901
trols in the Taiwanese series ( ) (table 2).Pp .091
The present results point to differential risk effects of
SEMA5A marker alleles across populations. In the Tai-
wanese population, we have found an associated risk in
the same locus as the one reported elsewhere1 but in an
opposite direction. That is, the at-risk allele that we re-
port was found to be protective in the sample from Min-
nesota described by Maraganore et al.1 This could be
due to the effect of LD between this polymorphism and
another “true” risk variant within the gene. The lack of
association shown in the Finnish population could be
related to genetic heterogeneity, or, alternatively, the
Finnish series might not be large enough to assess genes
with modest effects (this sample has a 60% power to
detect risks of 1.7, at ).ap 0.05
The replication of an association with SEMA5A in a
Taiwanese population makes it a good candidate for
further analyses in different populations.
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Web Resources
The URLs for data presented herein are as follows:
dbSNP, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMDpsearch
&DBpsnp (for SEMA5A markers)
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm
.nih.gov/entrez/Omim/ (for PD and SEMA5A)
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